A global action agenda for turning the tide on fatty liver disease

Healthy Livers, Healthy Lives Collaborators

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Background and Aims: Fatty liver disease is a major public health threat due to its very high prevalence and related morbidity and mortality. Focused and dedicated interventions are urgently needed to target disease prevention, treatment, and care. Approach and Results: We developed an aligned, prioritized action agenda for the global fatty liver disease community of practice. Following a Delphi methodology over 2 rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the action priorities using Qualtrics XM, indicating agreement using a 4-point Likert-scale and providing written feedback. Priorities were revised between rounds, and in R2, panelists also ranked the priorities within 6 domains: epidemiology, treatment and care, models of care, education and awareness, patient and community perspectives, and leadership and public health policy. The consensus fatty liver disease action agenda encompasses 29 priorities. In R2, the mean percentage of "agree"responses was 82.4%, with all individual priorities having at least a super-majority of agreement (> 66.7% "agree"). The highest-ranked action priorities included collaboration between liver specialists and primary care doctors on early diagnosis, action to address the needs of people living with multiple morbidities, and the incorporation of fatty liver disease into relevant non-communicable disease strategies and guidance. Conclusions: This consensus-driven multidisciplinary fatty liver disease action agenda developed by care providers, clinical researchers, and public health and policy experts provides a path to reduce the prevalence of fatty liver disease and improve health outcomes. To implement this agenda, concerted efforts will be needed at the global, regional, and national levels.

Original languageEnglish
Pages (from-to)502-523
Number of pages22
JournalHepatology
Volume79
Issue number2
DOIs
StatePublished - Feb 2024

Funding

FundersFunder number
Genentech-Roche
Helio Health
National Institutes of Health
GlaxoSmithKline
Gilead Sciences
Novo Nordisk

    Fingerprint

    Dive into the research topics of 'A global action agenda for turning the tide on fatty liver disease'. Together they form a unique fingerprint.

    Cite this